July 4, 2005

Takeda Pharmaceutical Company Limited

Takeda to Disclose Information on Clinical Trials in the Web site

Osaka, Japan, July 4, 2005 --- Takeda Pharmaceutical Company Limited ("Takeda") today announced to start disclosure of its clinical trials information in the web-site starting July 1, 2005. This new movement was to follow the joint positioning statement dated January 6 this year by the bodies collectively representing the pharmaceutical industry worldwide such as IFPMA, EFPIA, JPMA and PhRMA. (*)

(*)	IFPMA	:	International Federation of Pharmaceutical Manufacturers & Associations
	EFPIA	:	European Federation of Pharmaceutical Industries and Associations
	JPMA	:	Japanese Pharmaceutical Manufacturers Association
	PhRMA	:	Pharmaceutical Research and Manufacturers of America

Takeda has established the disclosure criteria taking into consideration the said positioning statement as follows:

• 1. Clinical trials accomplished on or after January 6, 2005 for a product that is marketed in any country of the world.Summary of mainly phase III and IV confirmatory clinical trial data including name of the product, clinical phase, purpose and methods, number of patients, endpoint, statistics, etc.

2. Clinical trials to be initiated on or after July 1, 2005

•   Summary of protocol of phase III and IV confirmatory clinical trials including development code, clinical phase, target disease, purpose, etc. In this case, summary of protocol is disclosed within 21 days from the start of enrolment of the patients.

The information of all the clinical trials meeting the above criteria will be posted in our Englishi web site, and as for those conducted in Japan, the information in Japanese is also posted in the web site. In addition, the protocols of the clinical trials in Japan meeting the above criteria 2 will be posted in the specific web site for clinical trials which is now under construction jointly by JPMA and JAPIC (Japan Pharmaceutical Information Center), while we are considering to post those in the US and Europe on the web site of the US NIH (National Institute of Health).

We expect that this disclosure assure the transparency of the information on the clinical trials for the healthcare profession, the patients and other related persons, which we believe will contribute to appropriate use of Takeda’s products worldwide.

Takeda, located in Osaka, Japan, is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products.

# # #